TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Vivesto AB ( (SE:VIVE) ).
Vivesto AB has announced positive interim results from a pilot study of Paccal Vet, a drug candidate for treating dogs with splenic hemangiosarcoma following splenectomy. The results suggest that Paccal Vet may extend the overall survival of affected dogs compared to historical controls, potentially leading to further studies and eventual marketing approval. This development could significantly impact the limited treatment options available for canine hemangiosarcoma, offering a new hope for improving the quality of life and survival rates in dogs diagnosed with this aggressive cancer.
More about Vivesto AB
Vivesto AB is a Swedish development company focused on oncology, aiming to provide new treatment options for hard-to-treat cancers with significant medical needs and market potential. Their project portfolio includes Cantrixil for blood cancer and the veterinary oncology program Paccal Vet, which is being evaluated in clinical trials for dogs with splenic hemangiosarcoma and in cats with solid tumors.
Average Trading Volume: 524,772
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK123.7M
Learn more about VIVE stock on TipRanks’ Stock Analysis page.